



Malaysian Society of Haematology

MALAYSIA MPN EXPERT FORUM

Early Stage Myelofibrosis: Personalized Clinical-Decision Tools & Treatment

Webcast

3rd April 2021 (Saturday)

3.00pm - 5.00pm

AGENDA

Time	Topic	Speaker
3:00 - 3:05 PM	Welcome remarks	Dr. Alan Teh(SJMC)
3:05 - 4:05 PM	Early-Stage Myelofibrosis - Personalized Clinical-Decision Tools and treatment	Prof Dr. Martin Griesshammer (Germany)
4:05 - 4:35 PM	Patients Case Study	Dr. Nor Rafeah Tumian(HUKM)
4:35 - 4:55 PM	Q & A	All
4:55 - 5:00 PM	Closing Remarks	Dr. Alan Teh(SJMC)



Chairperson
Dr. Alan Teh
Consultant Hematologist
Subang Jaya Medical Center

SPEAKERS



Professor Dr. Martin Griesshammer, Germany

Medical Director in the Department of Haematology, Haemostaseology, Oncology and Palliative Care at the Johannes Wesling University Clinic in Minden. Chair of Internal Medicine at the Johannes Wesling University Clinic. Prior to this appointment, he was Vice Head of the Department of Haematology and Oncology at the University of Ulm.

Under Professor Griesshammer's guidance, the Johannes Wesling University Clinic in Minden serves many haematological patients, providing outpatient and inpatient services, peripheral blood stem cell transplantation, haemostaseology, oncology and palliative care.



Dr. Nor Rafeah Tumian

Dr Nor Rafeah Tumian is a Clinical Haematologist and Lecturer at the Clinical Haematology Unit, Department of Medicine, Faculty of Medicine, UKM. She obtained both her medical degree (MD) in 2000 and subsequently MMed (Int. Med) in 2008 from Universiti Kebangsaan Malaysia. Her research interests focus on clinical research in malignant haematology in adults.

Management of infection in patients undergoing chemotherapy Infection, particularly neutropenic sepsis or febrile neutropenia, is a life threatening complication of chemotherapy and in the priority in any discussion on the side effects of chemotherapy. The incidence varies, and depends on the myelosuppressive nature of the chemotherapy drug/s being given, the performance status of the patient, and the extent of comorbid conditions. American Society of Clinical Oncology and Infectious Disease Society of America have published clinical practice guidelines to address this important condition.

[Click here for registration](#)

Note to all Public Officials: "We deem that you have obtained the appropriate approval from all relevant parties within your institution to attend this event."

PRIVACY NOTICE: By signing into this meeting link, you hereby authorize Novartis Malaysia and its affiliates to collect, process and store the information you provide through this virtual meeting (such as your name, IP addresses, information from cookies, web beacons or other similar tracking technology, as well as your image and voice if recording session is required) for proof of your attendance; subsequent follow up activities; as well as Novartis network infrastructure management and enhance user experience using this Novartis approved third party website / digital platform. Please also go through [Microsoft Privacy Policy](#) to understand what data is collected and how Microsoft uses that data. Novartis considers the protection of your personal data and privacy a very important matter. We shall process and protect your data in compliance with Malaysia Personal Data Protection Act. For any data privacy question please contact our Country Data Privacy Office at my.cdpo@novartis.com

Organized By:



For Healthcare Professionals Only

Novartis Corporation (Malaysia) Sdn Bhd (10920H)
Level 22, Tower B, Plaza 33, No. 1, Jalan Kemajuan, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan
Tel: +603 7948 1888 **Fax:** +603 7948 1818 www.novartis.com